LENSAR (LNSR) Q3 2026 earnings review
LENSAR's cataract procedures keep growing, but machine sales halved
LENSAR's lasers performed more cataract operations than a year ago, while its machine sales shrank. Total revenue slipped 1%, because customers bought fewer systems than in an unusually busy prior-year quarter. Repeat fees, which LENSAR collects each time a surgeon operates, covered 89% of revenue. Chief executive Nick Curtis said the company's market share reached 24.5%, and adjusted earnings turned positive with no tariff refund to help.
| Recurring revenue: fees per operation, leases and service | $12.6M +17% from a year ago |
|---|---|
| Total revenue | $14.1M -1% from a year ago |
| Adjusted profit before interest, tax and depreciation | $1.7M -$0.3M a year ago |
| Planned cash use for the rest of 2026 | $1-2 million $0.9 million used in the third quarter |
⚖️ Verdict: ⚪ Neutral
The case is unchanged, because its two halves moved in opposite directions. Profit quality improved: the margin gain held up without any one-off credit, and a new credit line pushed the cash question further out. One caution: LENSAR placed only 10 robotic lasers again and its order book thinned, so Curtis now points the hardware recovery into 2027 rather than this year.
The question now is whether LENSAR can sell machines at its old pace again. Curtis says overseas distributors are ordering once more and sees a recovery building through 2027; the other answer is that bundled rivals tied up those accounts during the Alcon year, leaving the laser base to creep along. The placement count for the fourth quarter, when the promised distributor deliveries fall due, settles it in February.
🐂 Bull Case
Surgeons Ran More Operations on LENSAR Lasers
LENSAR earns most of its money after a sale: every cataract operation on one of its lasers needs a single-use interface device and a licence fee. Chief executive Nick Curtis said the long-term value of the business "is not simply measured by how many systems we place in any one quarter".
Surgeons ran 52,545 operations on LENSAR lasers, about 12% above last year, even though summer holidays empty operating rooms. Fees from those operations grew 17%, and finance chief Mike Rossi credited a bigger installed base and heavier use of the machines in American practices.
- Recurring fees: $12.6 million, 89% of revenue
- Fees per operation: about $174, from $167, by our math
- Lasers installed: 450, of which 225 are ALLY robots
The machines already installed, not new sales, now set the revenue line, because each one earns fees for years. Operations grew faster than the laser base, which expanded 6%, so existing customers did more work with what they own.
What to watch: the fourth-quarter procedure count in February. Surgeons ran 54,756 operations on LENSAR lasers a year earlier, and a clear gain on that would show the base is winning new users.
Profit Improved Without a Tariff Refund
Three months ago LENSAR's best adjusted earnings leaned on a $1.1 million tariff refund booked against the cost of sales. No such credit arrived this time, and the profit stayed. Rossi reported gross margin of 58%, against 42% a year earlier, and adjusted earnings before interest, tax and depreciation of $1.7 million.
One cost line carries the move. The products LENSAR sells cost 24.7% of revenue to make, against 39.5% a year ago by our math, because fee income replaced hardware; the finance chief put procedure revenue at "80% gross margin basically".
What to watch: the fourth-quarter margin against about 53%, the level Rossi called sustainable in August once the tariff refund is stripped out, by our math. He said service costs were unusually low this time and "probably won't repeat in the future", so a reading in the mid-50s would show the mix is doing the work.
LENSAR Took Share in a Slower Market
Curtis gave one figure for competition: LENSAR's market share reached 24.5%, "up from 24.1% in" the second quarter. Surgeons switching from a rival's femtosecond laser drove part of that, he said; the rest came from surgeons who had never used a laser on a cataract.
The second group matters more, because it widens the market instead of splitting it. Curtis said "42% of our installs over the last 12 months have been with these surgeons that were heretofore not using lasers", while total American cataract volumes slipped a little.
What to watch: the share reading with the annual results, and whether American cataract volumes recover. Share that stops climbing in a shrinking market would leave procedure fees growing only as fast as the laser base.
🐻 Bear Case
System Sales Halved and the Order Book Thinned
The release headline counts 10 ALLY robotic lasers placed and an installed base up 22%. It leaves out the comparison: in the same quarter last year LENSAR placed 18 and held 18 more on order. This time it placed 10 and ended September with 12 awaiting installation.
Capital sales show the effect: $1.5 million, against $3.5 million a year earlier. Over nine months those sales fell 41%, by our math. Curtis explained the overseas part, because as the Alcon takeover neared its end "the distributors really were thinking it was the end of their relationship with LENSAR", so orders stopped.
Every laser installed becomes an annuity of procedure fees, so today's placement rate sets the growth rate two years out. Curtis called the business outside America "kind of a work in progress" and said he is "counting on OUS to deliver some robust business to us here as we get into mid-2027" - later than the recovery LENSAR described in May.
What to watch: placements and the order book with the annual results in February. Distributor orders promised for the fourth quarter are the test, and a count in the mid-teens with a bigger order book behind it would show the recovery has begun.
Thin Cash and a Big Share Overhang
LENSAR held $12.6 million in cash and investments at the end of September, against $18.0 million at the start of the year. Rossi put the quarter's cash use at $900,000, which he called "an improvement over historical trends". A new $10 million revolving credit line, secured during the quarter, takes available liquidity to $22.6 million.
The improvement is real but narrow. Placing fewer lasers also ties up less cash in equipment, so part of the smaller outflow comes from the weak quarter itself. Even so, $5.4 million has left the balance sheet since December, while the nine-month operating result, excluding merger credits and project costs, came out roughly level by our math.
The dilution risk has not changed. Preferred shares and warrants, held largely by one investor with two board seats, convert into about 12.3 million shares - roughly the number of ordinary shares in issue. Those same terms restrict new borrowing above $1 million without the holder's agreement, and LENSAR said nothing about that consent.
What to watch: cash and investments at the end of December, against the $1 million to $2 million of use Rossi described for the rest of 2026. A figure near $11 million, by our math, would mean operations now pay for the stock and the leftover merger bills.
Risks This Quarter Didn't Answer
Four standing worries got no new numbers from LENSAR this time. Each needs a disclosure that neither the release nor the call contained, and the quarterly filing or February's annual results are where each would appear.
- Profit quality: Rossi said "services costs were just low for the quarter, which was just lower activity there than normal", and selling and administrative spending has already returned to $8.1 million from $6.1 million; no normal quarterly level named.
- Tariffs: no word on whether LENSAR still absorbs tariff costs rather than charging customers, or whether further refunds are due.
- Pricing against bundled rivals: Curtis described competitive wins, but gave no pricing detail for the large practice groups that buy lenses and lasers together.
- Finance leadership: Rossi remains interim finance chief through the rebuild, and LENSAR has named no permanent appointment.
What to watch: the quarterly filing's expense and tariff notes, due within days. A normalized cost level and a tariff update would let a reader judge how much of this quarter's profit repeats next year.
👓 Other Themes
Automated Docking Arrives in Early 2027
At the AAO annual meeting LENSAR showed new docking features, in which "the system will both locate and dock to the patient's eye on a fully automated basis". Curtis said "we anticipate introducing these features by the end of the first quarter of 2027", and on the call extended that into the second quarter. No revenue depends on them yet.
Germany and Switzerland Changed Payment Rules
Curtis named two conditions outside LENSAR's control. Doctors returned from holiday to "some changes in reimbursement that came into play outside U.S. and particularly in Germany and Switzerland", one of its strongest markets; he said activity there is returning. In America, total cataract volumes dipped, "the first time in the history I've been in business" that he has seen the market slow.
💲 Other KPIs
Stock keeps building: up 22% from a year ago and $3.6 million higher than in December, while capital sales fell. The holding now equals 2.9 times the system revenue of the past four quarters, by our math, so working capital is absorbing the cash the recovery generates.
LENSAR is paying down the bills left by the abandoned Alcon takeover: the total has fallen 38% since December. Accrued liabilities also came down, to $6.4 million from $7.8 million. Those payments, rather than trading losses, explain most of this year's cash outflow.
This balance explains the reported loss. LENSAR carries the warrants at market value, and the balance rose during the quarter, which the income statement records as a non-cash charge of $3.4 million. That is how a $1.4 million operating loss became a $4.7 million net loss; earlier in the year the same line produced large gains.
🔮 Guidance
New. Rossi expects "$1 million to $2 million of kind of cash kind of burn in the rest of the year", more than the $900,000 used between July and September. He named stock buying and deferred Alcon fees as the reasons. By our math that leaves roughly $11 million of cash and investments at the end of December, before anything drawn on the new credit line.
New. The finance chief said LENSAR "should get closer to breakeven at some point in 2027" on cash, which lags the adjusted earnings already reported: those were positive in each of the past two quarters. The gap is working capital - stock, receivables and the remaining merger bills - rather than trading.
Unchanged. Curtis still points to procedure fees as the engine and gives no number. He said practices moving from an older LENSAR laser to ALLY typically see "a 15% thereabouts increase" in volume once trained. Each installed laser ran about 117 operations this quarter against 132 in the spring, a seasonal dip rather than a change of direction.
Cut. In May LENSAR said placements would return to historical levels within a few quarters. Asked about 2027, Curtis now says only "I think you're going to see a ramp there" and puts the overseas contribution at mid-2027. He also warned that "you'll see where the installed base may flatten for a period of time", because older lasers move to new sites instead of being replaced.
Held. Rossi said this quarter's figure included service costs that "probably won't repeat in the future", so August's sustainable level remains the better marker. Mix still helps, because procedure fees earn about 80% at the gross level and now make up most of revenue; a quarter with more capital sales would pull the percentage back down.
❓ Key Questions
What counts as a normal quarterly cost base?
Selling and administrative spending went from $6.1 million to $8.1 million in three months, $1.2 million of it on new commercial projects. Readers cannot judge the profit run rate until LENSAR names the level it regards as normal.
Did the preferred holder approve the credit line?
The preferred terms restrict borrowing above $1 million without the holder's consent, and that holder has two board seats. LENSAR did not say whether the holder agreed, or how much it can actually draw on the $10 million facility.
How many systems arrive in the fourth quarter?
In August LENSAR said distributor orders outside America were set mainly for fourth-quarter delivery. The placement count, and the order book left behind it, decide whether the capital-sales recovery has started.
How do American and overseas procedures compare?
Curtis says America runs ahead on both systems and volumes and calls the rest of the world a work in progress. A split of operations by region would show how much of the fee growth rests on one market.
Are more tariff refunds due, and who pays the tariffs?
A $1.1 million refund flattered last quarter's margin, and LENSAR has not said whether it still absorbs tariff costs instead of charging customers. The answer sets the cost of every device it ships.